newsfilter
← Latest News
PR Newswire·

Elanco Animal Health Reports Third Quarter 2026 Results

ELAN
  • Elanco Animal Health reported third quarter 2026 revenue of $1.265 billion, representing an 11% year-over-year increase and 9% organic constant currency growth.
  • The company achieved reported net income of $18 million with adjusted net income of $136 million, resulting in adjusted earnings per share of $0.27.
  • Adjusted EBITDA reached $243 million with a margin of 19.5%, while the net leverage ratio improved to 2.9x adjusted EBITDA.
  • Pet Health revenue grew 14% to $608 million, driven by a 5% price increase and strong demand for Zenrelia and Credelio Quattro.
  • Farm Animal revenue increased 6% to $631 million, with the cattle segment growing 17% year-over-year.
  • Elanco raised its full year 2026 revenue guidance to $5.155 billion to $5.18 billion and adjusted EBITDA guidance to $1.05 billion to $1.065 billion.
  • The adjusted EPS guidance for the full year 2026 was increased to a range of $1.17 to $1.20.
  • Innovation revenue targets for 2026 were raised to $1.275 billion.
  • Zenrelia recorded its largest revenue quarter ever, while Credelio Quattro became the largest U.S. Pet Health branded product, surpassing Seresto.
  • Credelio Quattro received a positive European Medicines Agency opinion for an EU expansion expected in Q1 2027.
  • Befrena access is now open across clinics with a full launch planned for Q1 2027.
  • Jamie Preston was appointed Executive Vice President and Chief People Officer effective November 3, 2026.
  • The company provided Q4 2026 guidance with revenue expected between $1.19 billion and $1.215 billion.
  • Early outlook for 2027 projects mid-single digit organic constant currency revenue growth, high-single digit adjusted EBITDA growth, and low-double digit adjusted EPS growth.
Company
Elanco Animal Health
Keywords
Elanco Animal Health